Introducing the BenevolentAI and UCL PhDs

Inviting students to train as the experts of tomorrow in applying machine learning to human genetics and electronic health records. The UCL Centre for Translational Genomics (CTG) and Institute for Health Informatics (IHI) are international centres of excellence for research in these two areas and we are excited about further strengthening our already established links with them both.

Read More
Our team behind the scenes at SXSW - designing better medicines using AI and big data

We brought our Benevolent Team to SXSW to share our collective vision of using the power of technology to solve something that truly matters to the world, for us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

Read More
New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca. This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

Read More
Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated. We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

Read More
BenevolentAI Awarded Technology Pioneer Status by World Economic Forum

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Read More
Love drug discovery? You just need the right chemistry!

There is an increasing number of varieties of drug agents in clinical use ranging from antibodies and proteins to nucleic acids and, increasingly, cellular and genetic therapies but the majority of drugs on the market and in development today are still small, synthetic molecules made in a chemistry laboratory.

Read More
Counting down to the BenevolentAI Award

It’s now only a number of days until we announce the winner of the first BenevolentAI award on March 28th. Since applications closed in late January, the process has been one my fellow judges, Aisling Burnand, CEO of Association of Medical Research Charities (AMRC), and Neil Lawrence, Director of Machine Learning of Amazon Research Cambridge and I have found enjoyable, insightful and richly rewarding.

Read More